Skip to main content
SpringerLink
Log in

Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Although the classification of insular glioma has been established based on the anatomical location in order to facilitate personalized surgical resection, the diagnosis based on anatomical and functional characteristics becomes more complex when insular tumors extend into either the frontobasal brain region and/or the temporal lobe, as part of the limbic system. Moreover, prognosis of insular tumor resection is still controversial. Further analysis of subgroup characteristics of insular grade II gliomas based on clinical and molecular analysis is required to reliably determine patients’ survival rates. In this retrospective study 20 purely insular grade II gliomas patients and 22 paralimbic grade II gliomas that involved frontal and/or temporal lobes were compared with regard to epidemiological and clinical characteristics. The molecular profiles including Isocitrate dehydrogenase 1 (IDH1), telomerase reverse transcriptase (TERT) promoter, and P53 mutations, 1p19q co-deletion were analyzed, and microRNA profiles were assessed by microarray and bioinformatics analysis. Purely insular grade II gliomas displayed a high frequency of IDH1 mutations with favorable outcome. IDH1 mutated paralimbic glioma shared many parameters with the purely insular glioma in respect to growth patterns, survival, and microRNA profile, but differed significantly from the IDH1 wild type paralimbic gliomas. Our findings suggest that IDH1 mutations can define subpopulations of insular gliomas with distinct disease entities regardless of tumor extension patterns. These findings could be useful to develop a customized treatment strategy for insular glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shelley BP, Trimble MR (2004) The insular lobe of Reil—its anatamico-functional, behavioural and neuropsychiatric attributes in humans—a review. World J Biol Psychiatry 5:176–200

    Article  PubMed  Google Scholar 

  2. Ture U, Yasargil DC, Al-Mefty O, Yasargil MG (1999) Topographic anatomy of the insular region. J Neurosurg 90:720–733

    Article  PubMed  CAS  Google Scholar 

  3. Yasargil MG, von Ammon K, Cavazos E, Doczi T, Reeves JD, Roth P (1992) Tumours of the limbic and paralimbic systems. Acta Neurochir (Wien) 118:40–52

    Article  CAS  Google Scholar 

  4. Wu AS, Witgert ME, Lang FF, Xiao L, Bekele BN, Meyers CA, Ferson D, Wefel JS (2011) Neurocognitive function before and after surgery for insular gliomas. J Neurosurg 115:1115–1125

    Article  PubMed  Google Scholar 

  5. Duffau H, Taillandier L, Gatignol P, Capelle L (2006) The insular lobe and brain plasticity: lessons from tumor surgery. Clin Neurol Neurosurg 108:543–548

    Article  PubMed  Google Scholar 

  6. Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100:2622–2626

    Article  PubMed  Google Scholar 

  7. Mehrkens JH, Kreth FW, Muacevic A, Ostertag CB (2004) Long term course of WHO grade II astrocytomas of the Insula of Reil after I-125 interstitial irradiation. J Neurol 251:1455–1464

    Article  PubMed  Google Scholar 

  8. Sanai N, Polley MY, Berger MS (2010) Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg 112:1–9

    Article  PubMed  Google Scholar 

  9. Goze C, Mansour L, Rigau V, Duffau H (2013) Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. J Neurosurg 118:866–872

    Article  PubMed  CAS  Google Scholar 

  10. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LJ, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Zhang C, Moore LM, Li X, Yung WK, Zhang W (2013) IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol 15:1114–1126

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK (2015) TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol 28:177–186

    Article  PubMed  CAS  Google Scholar 

  13. Wang Z, Bao Z, Yan W, You G, Wang Y, Li X, Zhang W (2013) Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res 32:59

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Wang Y, Zhang T, Li S, Fan X, Ma J, Wang L, Jiang T (2015) Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Eur J Neurol 22:348–354

    Article  PubMed  CAS  Google Scholar 

  16. Gilbertson RJ, Gutmann DH (2007) Tumorigenesis in the brain: location, location, location. Cancer Res 67:5579–5582

    Article  PubMed  CAS  Google Scholar 

  17. Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H (2012) A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 22:2339–2355

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Zhou X, Ruan J, Wang G, Zhang W (2007) Characterization and identification of microRNA core promoters in four model species. PLoS Comput Biol 3:e37

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mandonnet E, Capelle L, Duffau H (2006) Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns. J Neurooncol 78:179–185

    Article  PubMed  Google Scholar 

  21. Hu H, Wang Z, Liu Y, Zhang C, Li M, Zhang W, Wang K, Cai J, Cheng W, Huang H, Jiang T (2015) Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. Cancer Lett 357:566–574

    Article  PubMed  CAS  Google Scholar 

  22. Skrap M, Mondani M, Tomasino B, Weis L, Budai R, Pauletto G, Eleopra R, Fadiga L, Ius T (2012) Surgery of insular nonenhancing gliomas: volumetric analysis of tumoral resection, clinical outcome, and survival in a consecutive series of 66 cases. Neurosurgery 70(1081–1093):1093–1094

    Google Scholar 

  23. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Skrap M, Mondani M, Tomasino B, Weis L, Budai R, Pauletto G, Eleopra R, Fadiga L, Ius T (2012) Surgery of insular nonenhancing gliomas: volumetric analysis of tumoral resection, clinical outcome, and survival in a consecutive series of 66 cases. Neurosurgery 70(1081–1093):1093–1094

    Google Scholar 

  25. Sanai N, Polley MY, Berger MS (2010) Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg 112:1–9

    Article  PubMed  Google Scholar 

  26. Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y (2015) TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget. [Epub ahead of print]

Download references

Acknowledgments

This work was supported by grant 13JC1408000 from the Science and Technology Commission of Shanghai Municipality (to Liang-fu Zhou), the Research Special Fund For Public Welfare Industry of Health (No. 201402008) to Yao Yu, the National Key Clinical Specialist Construction Programs of China (Oncology) to Liang-fu Zhou.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Huashan Hospital, Fudan University, No. 12 Wulumuqi Middle Road, Shanghai, 200040, China

    Chao Tang, Zhen-yu Zhang, Ling-chao Chen, Zelin Sun, Yi Zhang, Zhiyong Qin, Yu Yao & Liang-fu Zhou

  2. Neurosurgical Immunology Laboratory of Huashan Hospital, Fudan University, No. 12 Wulumuqi Middle Road, Shanghai, 200040, China

    Chao Tang, Ling-chao Chen & Yu Yao

Authors
  1. Chao Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhen-yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ling-chao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zelin Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhiyong Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liang-fu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yu Yao or Liang-fu Zhou.

Ethics declarations

Conflict of interest

The authors have declared that no competing interests exist.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, C., Zhang, Zy., Chen, Lc. et al. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. J Neurooncol 126, 499–507 (2016). https://doi.org/10.1007/s11060-015-1989-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-015-1989-5

Keywords

Search

Navigation